Company news
Kamada Ltd. news in 2020
Kamada Ltd.'s news releases, calls and decks from 2020, newest first.
Kamada Added to the NASDAQ Biotechnology Index
December 20, 2020
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development
November 10, 2020
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
November 3, 2020
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
October 18, 2020
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
October 6, 2020
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
September 7, 2020
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective
August 18, 2020
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position
August 11, 2020
Kamada Announces Changes to its Board of Directors
August 11, 2020
Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
August 9, 2020
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
August 4, 2020